Aliskiren: the first direct renin inhibitor for hypertension.
Aliskiren is the first member of a novel class of antihypertensive agents, the renin inhibitors, that has been approved by the US Food and Drug Administration for the treatment of hypertension. This review discusses its potential differences compared with existing renin-angiotensin-aldosterone system blockers, focusing also on the inactive precursor of renin, prorenin, and the recently discovered (pro)renin receptor. The review summarizes the findings from all clinical trials with aliskiren published so far, and provides an overview of the safety and tolerability of the new drug.
van den Meiracker
Anton H
AH
Division of Vascular Pharmacology and Metabolism, Room EE1418b, Department of Internal Medicine, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, Netherlands.
Jan Danser
A H
AH
D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005650:Fumarates / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011956:Receptors, Cell Surface / Q000187:drug effects; D012083:Renin / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects; D025262:Vacuolar Proton-Translocating ATPases / Q000187:drug effects; D000092502:Renin Inhibitors; D000093342:Prorenin Receptor
D000577:Amides; D000959:Antihypertensive Agents; D005650:Fumarates; D011956:Receptors, Cell Surface; D012083:Renin; D025262:Vacuolar Proton-Translocating ATPases; D000092502:Renin Inhibitors; C458319:ATP6AP2 protein, human; D000093342:Prorenin Receptor; C446481:aliskiren